Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Contributed by: PR Newswire

Tags

Dawn-Health-Ekiva-PNH

More Like This

Dawn Health and Merck are collaborating to support Growth Disorders care

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH

PR Newswire associated0

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024

PR Newswire associated0

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

PR Newswire associated0

Octapharma to present new clinical and scientific data at ASH 2023 from ongoing research initiatives aimed at advancing care for people living with bleeding disorders

Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

PR Newswire associated0

Department of Health - Abu Dhabi and Novartis to Partner to Advance Genomics Research in Oncology and Beyond